Stock Analiz

Nektar Therapeutics (NKTR) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Nektar Therapeutics’s revenue went from $165M in fiscal 2016 to $55M in fiscal 2025, a decline of about 11.5% a year.

Net income in fiscal 2025 was -$164M, a net margin of -297.1%; the best year in this period was 2018 with $681M.

Over the twelve months to September 30, 2026, revenue was $52M and net income -$177M.

Free cash flow was -$209M in fiscal 2025 and positive in 1 of the 10 years shown.

The diluted share count rose 81% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $165M162017: $308M172018: $1.2B182019: $115M192020: $153M202021: $102M212022: $92M222023: $90M232024: $98M242025: $55M25$55M
Net income
2016: -$154M162017: -$97M172018: $681M182019: -$441M192020: -$444M202021: -$524M212022: -$368M222023: -$276M232024: -$119M242025: -$164M25-$164M
Free cash flow
2016: -$123M162017: -$90M172018: $704M182019: -$355M192020: -$321M202021: -$428M212022: -$310M222023: -$193M232024: -$177M242025: -$209M25-$209M
EPS (diluted)
2016: $-8.25162017: $-4.65172018: $28.35182019: $-18.90192020: $-18.67202021: $-21.45212022: $-14.77222023: $-10.87232024: $-4.34242025: $-4.8725$-4.87

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$52M$55M$98M$90M$92M$102M$153M$115M$1.2B$308M$165M
Gross profit—$55M$68M$56M$70M$77M$133M$93M$1.2B$277M$135M
Operating income-$167M-$140M-$105M-$264M-$376M-$446M-$425M-$440M$688M-$60M-$113M
Net income-$177M-$164M-$119M-$276M-$368M-$524M-$444M-$441M$681M-$97M-$154M
EPS (diluted)$-5.25$-4.87$-4.34$-10.87$-14.77$-21.45$-18.67$-18.90$28.35$-4.65$-8.25
R&D$149M$117M$121M$114M$218M$400M$409M$435M$400M$268M$204M
Revenue growth—−43.9%+9.2%−2.1%−9.7%−33.4%+33.4%−90.4%+287.8%+86.0%−28.3%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$257M-$209M-$176M-$193M-$304M-$413M-$313M-$329M$718M-$80M-$117M
Capital spending-$528000-$171000-$1M-$865000-$6M-$15M-$7M-$26M-$14M-$10M-$6M
Free cash flow-$257M-$209M-$177M-$193M-$310M-$428M-$321M-$355M$704M-$90M-$123M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks—$0$3M$0———————
Stock-based pay$13M$13M$22M$33M$57M$95M$94M$100M$88M$37M$26M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$246M$255M$304M$505M$734M$1.1B$1.3B$1.3B$296M$60M
Debt—$86M$103M$118M$131M$143M$150M$405M$250M$250M$250M
Equity—$90M$61M$131M$367M$680M$1.1B$1.4B$1.7B$88M$88M
Total assets—$280M$304M$398M$711M$1.1B$1.5B$2.0B$2.2B$509M$569M
Shares (diluted)—34M27M25M25M24M24M23M24M21M19M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—100.0%68.8%62.5%76.5%75.6%87.3%81.3%98.0%90.1%81.7%
Operating margin-319.8%-253.7%-106.9%-292.6%-408.6%-437.8%-278.0%-383.9%57.6%-19.4%-68.2%
Net margin-339.7%-297.1%-120.9%-306.3%-400.0%-514.0%-290.6%-384.5%57.1%-31.4%-92.8%
FCF margin-493.4%-377.8%-180.0%-214.7%-336.4%-419.7%-209.6%-309.7%59.0%-29.3%-74.6%
ROIC—-79.7%-64.3%-105.9%-59.7%-42.8%-27.4%-19.2%34.9%-14.0%-26.4%
ROE—-182.7%-195.9%-210.8%-100.4%-77.1%-41.3%-31.4%39.7%-110.1%-174.2%

Frequently asked questions

What is Nektar Therapeutics’s annual revenue?

$55M in fiscal 2025 and $52M over the twelve months to September 30, 2026.

How much profit does Nektar Therapeutics make?

Net income was -$164M in fiscal 2025 (net margin -297.1%).

Is Nektar Therapeutics’s revenue growing?

No: revenue fell 43.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.